 |
|
New treatment option studied for bladder cancer
October 30, 2007A chemotherapy regimen for patients with advanced bladder cancer who aren't eligible for standard treatment is under study at the Medical College of Georgia.
The unfortunate reality is that kidney problems often result from bladder cancer which precludes the usual chemotherapy package of cisplatin and gemcitabine, says Dr. Teresa A. Coleman, hematologist-oncologist at the MCG Cancer Center.
A Phase II study at about 120 sites in North America, Europe and Asia will determine if those patients can benefit from vinflunine, which is in the same vinca alkaloid family as Navelbine®, used for lung cancer.
These vinca alkaloids keep cells from dividing properly so the tumor can't grow and existing tumor regresses, says Dr. Coleman, a principal investigator on the study sponsored by Bristol-Myers Squibb.
Patients with stage two disease, which has spread beyond its origin in the bladder's lining, typically get cisplatin and gemcitabine before or after surgery or in conjunction with radiation therapy. However, a major side effect of cisplatin is kidney failure, and gemcitabine alone is believed not to be nearly as effective. "The most effective drug we have can't be used in some patients," Dr. Coleman says.
Bladder cancer, the sixth most common cancer, often obstructs tubules that connect the kidney to the bladder, says Dr. Coleman. While the cancer typically doesn't spread upward, tubule blockage damages the kidneys. Additionally, bladder cancer incidence peaks in the 60s and 70s when other diseases, such as type 2 diabetes and uncontrolled blood pressure, may also have damaged the kidneys, she says. These scenarios make more than 50 percent of patients age 70 to 80 and an estimated 30 percent of all bladder cancer patients are ineligible for cisplatin.
"I see so many patients who come to my office with kidney damage for a variety of reasons, and I have little for them really," says Dr. Coleman. A chemotherapy regimen that includes the drug carboplatin instead of cisplatin - both platinum-based compounds that also keep cancer cells from dividing - is more kidney friendly but less effective than the cisplatin regimen, studies have shown. Bristol-Myers Squibb produces cisplatin and carboplatin.
Participants will either get vinflunine and gemcitabine or gemcitabine alone. They will get the drug regimen intravenously on days one and eight of a 21-day cycle. Patients who do well may continue taking it up to a year or more.
Anemia is the major side effect of vinflunine, which suppresses the bone marrow, but existing anemia does not exclude patients from the trial, Dr. Coleman says.
She hopes the regimen will be at least as effective as the cisplatin therapy, which give patients with non-metastatic disease about a 50-50 chance of living five years. An earlier study in patients with advanced cancer who received a previous chemotherapy regimen, then vinflunine alone, showed 67 percent had their disease stabilized.
Smoking is the number-one risk factor for bladder cancer. The first symptom is often blood in the urine. "Bladder cancer begins in the urinary lining of the bladder," says Dr. Coleman. "When that lining is disrupted, it's like pulling layers of skin off. You will bleed into your urine. You can have pain, but that's usually a later sign."
Physicians will examine the lining and take a biopsy to determine the extent of the cancer. "If you catch it early, it's absolutely curable," Dr. Coleman says. Physicians literally tear off the diseased lining, which will eventually re-grow. If it's the early stage- one disease, but an aggressive form, BCG, an agent used as a vaccine for tuberculosis that stimulates an immune response, is injected directly into the bladder once a week for six weeks.
The fact that the bladder is literally a sac makes it a target for cancer by holding liquid toxic waste from a smoker's body, Dr. Coleman says. However, it also means that some patients can get localized treatment for their disease.
Medical College of Georgia
These vinca alkaloids keep cells from dividing properly so the tumor can't grow and existing tumor regresses, says Dr. Coleman, a principal investigator on the study sponsored by Bristol-Myers Squibb.
Patients with stage two disease, which has spread beyond its origin in the bladder's lining, typically get cisplatin and gemcitabine before or after surgery or in conjunction with radiation therapy. However, a major side effect of cisplatin is kidney failure, and gemcitabine alone is believed not to be nearly as effective. "The most effective drug we have can't be used in some patients," Dr. Coleman says.
Bladder cancer, the sixth most common cancer, often obstructs tubules that connect the kidney to the bladder, says Dr. Coleman. While the cancer typically doesn't spread upward, tubule blockage damages the kidneys. Additionally, bladder cancer incidence peaks in the 60s and 70s when other diseases, such as type 2 diabetes and uncontrolled blood pressure, may also have damaged the kidneys, she says. These scenarios make more than 50 percent of patients age 70 to 80 and an estimated 30 percent of all bladder cancer patients are ineligible for cisplatin.
"I see so many patients who come to my office with kidney damage for a variety of reasons, and I have little for them really," says Dr. Coleman. A chemotherapy regimen that includes the drug carboplatin instead of cisplatin - both platinum-based compounds that also keep cancer cells from dividing - is more kidney friendly but less effective than the cisplatin regimen, studies have shown. Bristol-Myers Squibb produces cisplatin and carboplatin.
Participants will either get vinflunine and gemcitabine or gemcitabine alone. They will get the drug regimen intravenously on days one and eight of a 21-day cycle. Patients who do well may continue taking it up to a year or more.
Anemia is the major side effect of vinflunine, which suppresses the bone marrow, but existing anemia does not exclude patients from the trial, Dr. Coleman says.
She hopes the regimen will be at least as effective as the cisplatin therapy, which give patients with non-metastatic disease about a 50-50 chance of living five years. An earlier study in patients with advanced cancer who received a previous chemotherapy regimen, then vinflunine alone, showed 67 percent had their disease stabilized.
Smoking is the number-one risk factor for bladder cancer. The first symptom is often blood in the urine. "Bladder cancer begins in the urinary lining of the bladder," says Dr. Coleman. "When that lining is disrupted, it's like pulling layers of skin off. You will bleed into your urine. You can have pain, but that's usually a later sign."
Physicians will examine the lining and take a biopsy to determine the extent of the cancer. "If you catch it early, it's absolutely curable," Dr. Coleman says. Physicians literally tear off the diseased lining, which will eventually re-grow. If it's the early stage- one disease, but an aggressive form, BCG, an agent used as a vaccine for tuberculosis that stimulates an immune response, is injected directly into the bladder once a week for six weeks.
The fact that the bladder is literally a sac makes it a target for cancer by holding liquid toxic waste from a smoker's body, Dr. Coleman says. However, it also means that some patients can get localized treatment for their disease.
Medical College of Georgia
Bladder Cancer Current Events and Bladder Cancer News RSSBladder cancer detected via amplified gene in cells found in urine
Counting the copies of a specific gene in cells gathered from a urine sample may provide a simple, noninvasive way to detect bladder cancer, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.
NewYork-Presbyterian/Columbia leads research into robotic surgery for kidney cancer
Clinical research at NewYork-Presbyterian Hospital/Columbia University Medical Center is helping bring the advantages of robotic surgery, including reduced pain and quicker recovery, to kidney cancer patients.
Patients unaware of link between smoking and bladder cancer
Even though cigarette smoking accounts for up to half of all bladder cancer cases, few people are aware of the connection - including more than three-quarters of patients who have bladder cancer.
Pregnancy may help protect against bladder cancer
Pregnancy seems to confer some protection against bladder cancer in mice, scientists have found.
Biomarker predicts malignancy potential of HG-PIN lesions in the prostate
Men whose prostate cancer screenings show high grade prostatic intraepithelial neoplasia (HG-PIN) may find themselves in limbo, "stuck" between diagnoses - they are told prostate cancer has not yet developed, but it might, and they are advised to undergo repeated needle biopsies as a precaution.
New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use.
UAB Study Shows Drug May Fight Biliary Cancers
Laboratory studies by University of Alabama at Birmingham (UAB) researchers have shown that the drug triphendiol (NV-196) causes cell death in pancreatic and bile duct cancer cell lines, slows tumor growth and sensitizes tumors to chemotherapy treatments.
Extract of broccoli sprouts may protect against bladder cancer
A concentrated extract of freeze dried broccoli sprouts cut development of bladder tumors in an animal model by more than half, according to a report in the March 1 issue of Cancer Research, a journal of the American Association for Cancer Research.
Study looks at new bladder cancer therapy for patients unresponsive to standard treatment
As many as half of patients with superficial bladder cancer do not respond to the standard first-line chemotherapy placed into the bladder, according to current multi-center outcomes data. When this happens, typically, their only option is surgical removal of the bladder.
Duke scientists map imprinted genes in human genome
Scientists at Duke University have created the first map of imprinted genes throughout the human genome, and they say a modern-day Rosetta stone - a form of artificial intelligence called machine learning - was the key to their success.
More Bladder Cancer Current Events and Bladder Cancer News Articles
 | Bladder Cancer (Cleveland Clinic Guide) by M D Raghavan, Kathleen Tuthill Cancer that arises in the bladder is one of the most common malignancies in industrialized societies and yet is not well understood in the community at large. Bladder Cancer: A Cleveland Clinic Guide provides simple, non-medical explanations of this disease for people who have to deal with this illness, either as patients or as those who care for these... |
 | Bladder Cancer: A Resource Guide for Patients and Their Families by Gary Dunetz If you, a loved one or friend has been diagnosed with bladder cancer, learning the basics is of utmost importance. It is essential to understand the nature of the disease, the work up and variety of treatments which are available. This book is comprehensive yet user friendly. It is written in a question and answer format in conversational tone. The physician author is a clinical urologist who has... |
 | 100 Questions & Answers About Bladder Cancer by Pamela Ellsworth, Brett Carswell Approximately 62,000 people are diagnosed with bladder cancer each year, making bladder cancer the fourth most common type of cancer in men and the eighth most common type in women. Whether you're a newly diagnosed bladder cancer patient, a survivor, or a friend or relative of either, this book offers help. The only book to provide both the doctor's and patient's views, 100 Questions & Answers... |
 | The Guide to Living with Bladder Cancer by Mark P. Schoenberg Bladder cancer is one of the most common cancers--and one of the least discussed. But bladder cancer, like other kinds of cancer, will greatly change the life of anyone who has the disease. Learning to live with the challenge of bladder cancer means getting good medical care, building a support group, and gathering as much information as you can. In The Guide to Living with Bladder Cancer, Dr.... |
 | Dx/ Rx: Genitourinary Oncology: Cancer of the Kidney, Bladder, and Testis (Dx/Rx Oncology) by Matthew Galsky Designed for both oncologists and urologists, Dx/Rx: Genitourinary Oncology is a current, concise, quick reference guide to the diagnosis and therapy of cancers of the bladder/urothelial tract, kidneys, and testis. Tightly organized into a super-condensed outline-bulleted format, this handy, pocket-sized manual details precise, up-to-date information on the epidemiology, classification,... |
 | Bladder Cancer: Current Diagnosis and Treatment (Current Clinical Urology) (Current Clinical Urology) Michael J. Droller, MD and a panel of experienced clinicians bring their strong background in clinical research to bear on the assessment and management of bladder cancer. Their comprehensive discussion summarizes the state-of-the-art in diagnosis and treatment, based on the latest understanding of bladder cancer's epidemiology, carcinogenesis, and tumor markers. Topics of particular interest... |
 | Treatment and Management of Bladder Cancer This second edition is expertly updated and follows the same easy to read format as the previous edition. Topics covered... |
 | Superficial Bladder Cancer by William R Fair Univ. of Padova, Italy. Report on the major advances and future of the field. Covers the full scope of superficial bladder cancer, from molecular biology to sophisticated forms of disease management. 32 contributors, 6... |
| Beware of bladder cancer: most bladder tumors are treatable and not deadly, but they require prompt medical attention. Make sure you know the signs.(Urology): An article from: Men's Health Advisor by Gale Reference Team This digital document is an article from Men's Health Advisor, published by Thomson Gale on July 1, 2007. The length of the article is 774 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Beware of... | |
 | Journey Through Cancer Land: One Man's Story of Cancer, Cancer Treatment and His Unexpected Encounters With God by John Harris, Cheryl Harris Your Insurance Companies and HMO's can Kill You!The book that John and Cheryl have written is hard-hitting – It contains graphic photos of failed bladder cancer surgery that disabled John. The authors deal with the problems they encountered with his health insurance company, HMO, group disability and group life insurance companies. It tells how the insurance companies tried to "cost contain"... |
| © 2008 BrightSurf.com |